<DOC>
	<DOCNO>NCT01352988</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic effect fumaric acid ester ( Fumaderm® ) treatment Cutaneous Lupus Erythematosus respect proportion responder base Revised Cutaneous Lupus Disease Area Severity Index ( RCLASI ) activity score skin lesion baseline 24 week treatment late assessment patient withdraw prematurely ( Last Observation Carried Forward , LOCF ) .</brief_summary>
	<brief_title>Efficacy Safety Fumaric Acid Esters ( Fumaderm® ) Treatment Patients With Cutaneous Lupus Erythematosus</brief_title>
	<detailed_description>At screening , patient meet inclusion exclusion criterion ask provide write informed consent . Male patient female patient without childbearing potential also complete screening procedure include vital sign , physical examination , patient physician efficacy assessment . Treatment start soon possible screening later 1 month screening . The patient receive treatment either Fumaderm® initial and/or Fumaderm® enteric-coated tablet . Fumaderm® initial usually administer first three week treatment / trial adaptation daily dosage require due occurrence adverse reaction , e.g gastrointestinal . Throughout trial , daily use sunscreen ( sun protection factor , SPF≥50 ) recommend patient . The management CLE may also involve use topical medication , topical steroid , systemic rescue medication , antimalarial . All patient evaluate RCLASI , PAGI VAS 12 week end treatment . Adverse Events ( AE ) record visit 4 week end therapy . Serious Adverse Events ( SAE ) must report occur 4 week end therapy .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>A clinical histological diagnosis CLE ( DLE , SCLE , LET , without major systemic involvement ) fail response topical corticosteroid ; Total RCLASI activity score &gt; 6 ( least 3 point least 2 location ) assessment erythema , scale/hyperkeratosis , edema/infiltration subcutaneous nodule/plaque lesion ( mucous membrane lesions/alopecia exclude ) ; Women childbearing potential must agree use least one primary method contraception preferably , time , secondary method contraception time screening , throughout trial treatment , least one month finish treatment . Signed informed consent . Patients unable comply requirement study ; Only scar cutaneous target lesion without activity ; Systemic Lupus Erythematosus ( SLE ) major systemic organ involvement , e.g . clinical significant renal involvement , require systemic medical treatment disease ; Active skin disease CLE another progressive serious disease interferes study outcome ; Symptoms clinically significant illness may influence outcome study four week study ; Active severe infection disease , include chronic localize ; Known malignancy last 5 year , effective treat non melanoma skin cancer ; Severe liver kidney disease ; Severe gastrointestinal disease , like gastric duodenal ulcer ; Severe hematologic disorder ; Patients leucopenia ( &lt; 3.000/mm³ ) ; Patients lymphopenia ( &lt; 500/mm³ ) ; Patients know hypersensitivity fumaric acid ester derivative , study medication component ; Topical corticosteroid within 14 day prior dose ; Local treatment fumaric acid derivates ; Initiation change dose current systemic medication treatment CLE/SLE prior study ( time depend drug class ) ; Treatment immunosuppressive drug reason , 4 week prior within study ; Concomitant treatment drug know photosensitize potential , e.g . tetracycline , griseofulvin , thiazide , furosemide , sulfonamide tolbutamide ; Drugs associate CLEinduction : terbinafine , hydrochlorothiazide , diltiazem , verapamil , nifedipine , nitrendipine , fluorouracil , penicillamine , infliximab , adalimumab , etanercept , pantoprazole ; Drugs interfering/ interact fumaric acid ester ; Drugs nephrotoxic potential , e.g . retinoids , psoralens , methotrexate , cyclosporine , immunosuppressant , cytostatics ; Participation another clinical trial include four week period precede study receive nonlicensed drug within last 3 month prior study ; Pregnancy ( accord pregnancy test ) nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>C17.300.475</keyword>
	<keyword>C17.800.480</keyword>
</DOC>